Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 85

Sort by

Sort Order Select

Journal Articles

Clinical Characteristics and Survival Outcomes of Patients with Primary and Secondary Plasma Cell Leukemia According to the 2021 Definition: A Single Center Retrospective Study

Khalid Shalaby, Farhan Azad, Sarah Parker, Katy Wang, Kristopher Attwood, Jens Hillengass

Blood (2024) 144 (Supplement 1): 6960.

https://doi.org/10.1182/blood-2024-198790

Published: 2024

Journal Articles

Six-Month Resistance Training Interventions Are Associated with Improvements in Fatigue and Pain in Multiple Myeloma Patients

Janine M. Joseph, Michaela Hillengass, Bryan J. Wittmeyer, Carolyn A. Miller, Hillary M. Jacobson, Kirsten B. Moysich, Rikki A. Cannioto, Jens Hillengass

Blood (2024) 144 (Supplement 1): 705.

https://doi.org/10.1182/blood-2024-211391

Published: 2024

Journal Articles

MRD By Flow Cytometry and FDG-PET/CT for the Post-Induction Response Assessment in Patients with Multiple Myeloma Treated in the Phase 3 GMMG HD7 Study

Marina Hajiyianni, Christos Sachpekidis, Annette Kopp-Schneider, Elias Karl Mai, Sandra Sauer, Ekaterina Menis, Michael Hundemer, Niels Weinhold, Jens Hillengass, Marc-Steffen Raab, Antonia Dimitrakopoulou-Strauss, Hartmut Goldschmidt

Blood (2024) 144 (Supplement 1): 4701.

https://doi.org/10.1182/blood-2024-210171

Published: 2024

Journal Articles

Differences in Immune Cell Populations between Individuals with or without MGUS

Sawyer Bawek, Janine M. Joseph, Alan Hutson, Sarah Parker, Joseph D. Tario Jr, Hamza Hassan, Scott I. Abrams, Jens Hillengass

Blood (2024) 144 (Supplement 1): 4678.

https://doi.org/10.1182/blood-2024-206171

Published: 2024

Journal Articles

Impact of Social Determinants of Health on Survival Outcomes in Multiple Myeloma Patients at a Major Cancer Center

Esraa Abdalla, Malak Alharbi, Sawyer Bawek, Catherine Forbes, Ian Lund, Han Yu, Berthliz Durand, Jens Hillengass, Hamza Hassan, Eugene Przespolewski

Blood (2024) 144 (Supplement 1): 5158.

https://doi.org/10.1182/blood-2024-206022

Published: 2024

Journal Articles

Results from the Completed Dose Escalation Portion of the Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (MM)

Sumit Madan, Caitlin L. Costello, Brea Lipe, Andrew J. Cowan, Eva Medvedova, Jens Hillengass, P. Leif Bergsagel, Xavier Leleu, Cyrille Touzeau, Daniel Morillo, Albert Oriol, Raya Mawad, Henning Schade, Salomon Manier, Yifah Yaron, Banmeet Anand, Al-Ola Abdallah

Blood (2023) 142 (Supplement 1): 1012.

https://doi.org/10.1182/blood-2023-182345

Published: 2023

Journal Articles

Safety and Tolerability of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Safety Run-in Results from a Phase 2 Study

Blood (2023) 142 (Supplement 1): 3383.

https://doi.org/10.1182/blood-2023-186997

Published: 2023

Journal Articles

Effects of Dose Reductions of Lenalidomide Given As Maintenance Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma

Ian Lund, Farhan Azad, Kristopher Attwood, Anthony George, Jens Hillengass

Blood (2023) 142 (Supplement 1): 3365.

https://doi.org/10.1182/blood-2023-181708

Published: 2023

Journal Articles

The Phase 2 CARTITUDE-2 Trial: Updated Efficacy and Safety of Ciltacabtagene Autoleucel in Patients with Multiple Myeloma and 1-3 Prior Lines of Therapy (Cohort A) and with Early Relapse after First Line Treatment (Cohort B)

Blood (2023) 142 (Supplement 1): 1021.

https://doi.org/10.1182/blood-2023-178882

Published: 2023

Journal Articles

Real-World Clinical Outcomes of Multiple Myeloma Patients with High-Risk Cytogenetics Treated with Dararvd, Single Center Experience

Sheeba Ba Aqeel, Alankrita Taneja, Adrienne Groman, Sarah Parker, Karan Jatwani, Arya Mariam Roy, Kristopher Attwood, Philip L. McCarthy, Jens Hillengass

Blood (2022) 140 (Supplement 1): 13216–13217.

https://doi.org/10.1182/blood-2022-165549

Published: 2022

Journal Articles

Immune Markers of Multiple Myeloma Patients Demonstrate Significant Change after Participation in Six-Month Physical Activity Intervention

Janine M. Joseph, Michaela Hillengass, Hillary Jacobson, Joseph D. Tario, Jr., Kristopher Attwood, Adrienne Groman, Rikki Cannioto, Bryan Wittmeyer, Kirsten Moysich, Scott I. Abrams, Jens Hillengass

Blood (2022) 140 (Supplement 1): 12630–12632.

https://doi.org/10.1182/blood-2022-167655

Published: 2022

Journal Articles

A Retrospective Study of Antibody Titers in Patients with Plasma Cell Disorders

Alankrita Taneja, Katy Wang, Sarah Parker, Sheeba Ba Aqeel, Joseph D. Tario, Jr., Hassan Awada, Arya Roy, Maximilian Merz, Philip L. McCarthy, Jens Hillengass

Blood (2022) 140 (Supplement 1): 10029–10030.

https://doi.org/10.1182/blood-2022-169163

Published: 2022

Journal Articles

Health-Related Quality of Life (HRQoL) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) Who Are Triple-Class Exposed to an Immunomodulatory Agent, a Proteasome Inhibitor, and an Anti-CD38 Antibody

Nina Shah, Ravi Vij, Jenna S. Roberts, Ivana Rajkovic, Rebecca Silbermann, Jens Hillengass, Sujith Dhanasiri, Julia Braverman, Abigail McMillan, Devender Dhanda

Blood (2022) 140 (Supplement 1): 13259–13261.

https://doi.org/10.1182/blood-2022-158235

Published: 2022

Journal Articles

Low Intake of Fruits and Vegetables and High Intake of Processed Meats and Juices Are Associated with Risk of MGUS in the National Health and Nutrition Examination Survey (NHANES) Database

Janine M. Joseph, Li Tang, Jens Hillengass, Kirsten Moysich, Ola Landgren, Saad Usmani, Alexander M Lesokhin, Susan E McCann, Urvi A Shah

Blood (2022) 140 (Supplement 1): 12556–12558.

https://doi.org/10.1182/blood-2022-167423

Published: 2022

Journal Articles

A Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Othman Salim Akhtar, Jens Hillengass, Brea Lipe, Sheila A. Figel, Robert A. Fenstermaker, Michael J. Ciesielski, Kelvin P. Lee

Blood (2022) 140 (Supplement 1): 10170–10171.

https://doi.org/10.1182/blood-2022-163597

Published: 2022

Journal Articles

Physical Activity in Patients with Monoclonal Gammopathies - a Healthtree Cure Hub Study

Jens Hillengass, Michaela Hillengass, Nathan W. Sweeney, Thomas H. Molina, Jennifer M. Ahlstrom, Rikki Cannioto, Kirsten Moysich, Janine M. Joseph

Blood (2022) 140 (Supplement 1): 7136–7137.

https://doi.org/10.1182/blood-2022-162327

Published: 2022

Journal Articles

Updated Interim Results from a Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (RRMM)

Al-Ola Abdallah, Andrew J Cowan, Xavier Leleu, Cyrille Touzeau, Brea Lipe, Eva Medvedova, Caitlin Costello, Jens Hillengass, P. Leif Bergsagel, Raya Mawad, Henning Schade, Daniel Morillo Giles, Albert Oriol, Yifah Yaron, Patrick P Ng, Sumit Madan

Blood (2022) 140 (Supplement 1): 7284–7285.

https://doi.org/10.1182/blood-2022-159665

Published: 2022

Journal Articles

Prediction of Malignant Cell Infiltration Patterns with Texture Features of Biopsy-Correlated Positron Emission Tomography of Osteolytic Lesions in Multiple Myeloma

Michael Laurence Langsen, Jerry Thwin Wong, Maximilian Merz, Brian Yu, Hemn Mohammadpour, Philip L. McCarthy, Jens Hillengass

Blood (2021) 138 (Supplement 1): 3997.

https://doi.org/10.1182/blood-2021-152846

Published: 2021

Journal Articles

Efficacy and Safety of Ciltacabtagene Autoleucel (Cilta-cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Lenalidomide-Refractory Patients with Progressive Multiple Myeloma after 1-3 Prior Lines of Therapy: Updated Results from CARTITUDE-2

Blood (2021) 138 (Supplement 1): 3866.

https://doi.org/10.1182/blood-2021-146072

Published: 2021

Journal Articles

Age, Sex and Self-Reported Race Differences in Immune Profiles of Hematologic Malignancy Patients

Megan M. Herr, Paul K. Wallace, Yali Zhang, George L. Chen, Sophia R. Balderman, Maureen Ross, Christine Ho, Jens Hillengass, Eunice S. Wang, Amanda Przespolewski, Elizabeth A. Griffiths, Pallawi Torka, Francisco J. Hernandez-Ilizaliturri, Paola Ghione, Philip L. McCarthy, Theresa E. Hahn

Blood (2021) 138 (Supplement 1): 4066.

https://doi.org/10.1182/blood-2021-150954

Published: 2021

NARROW

Clinical Characteristics and Survival Outcomes of Patients with Primary and Secondary Plasma Cell Leukemia According to the 2021 Definition: A Single Center Retrospective Study

Six-Month Resistance Training Interventions Are Associated with Improvements in Fatigue and Pain in Multiple Myeloma Patients

MRD By Flow Cytometry and FDG-PET/CT for the Post-Induction Response Assessment in Patients with Multiple Myeloma Treated in the Phase 3 GMMG HD7 Study

Differences in Immune Cell Populations between Individuals with or without MGUS

Impact of Social Determinants of Health on Survival Outcomes in Multiple Myeloma Patients at a Major Cancer Center

Results from the Completed Dose Escalation Portion of the Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (MM)

Safety and Tolerability of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Safety Run-in Results from a Phase 2 Study

Effects of Dose Reductions of Lenalidomide Given As Maintenance Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma

The Phase 2 CARTITUDE-2 Trial: Updated Efficacy and Safety of Ciltacabtagene Autoleucel in Patients with Multiple Myeloma and 1-3 Prior Lines of Therapy (Cohort A) and with Early Relapse after First Line Treatment (Cohort B)

Real-World Clinical Outcomes of Multiple Myeloma Patients with High-Risk Cytogenetics Treated with Dararvd, Single Center Experience

Immune Markers of Multiple Myeloma Patients Demonstrate Significant Change after Participation in Six-Month Physical Activity Intervention

A Retrospective Study of Antibody Titers in Patients with Plasma Cell Disorders

Health-Related Quality of Life (HRQoL) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) Who Are Triple-Class Exposed to an Immunomodulatory Agent, a Proteasome Inhibitor, and an Anti-CD38 Antibody

Low Intake of Fruits and Vegetables and High Intake of Processed Meats and Juices Are Associated with Risk of MGUS in the National Health and Nutrition Examination Survey (NHANES) Database

A Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Physical Activity in Patients with Monoclonal Gammopathies - a Healthtree Cure Hub Study

Updated Interim Results from a Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (RRMM)

Prediction of Malignant Cell Infiltration Patterns with Texture Features of Biopsy-Correlated Positron Emission Tomography of Osteolytic Lesions in Multiple Myeloma

Efficacy and Safety of Ciltacabtagene Autoleucel (Cilta-cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Lenalidomide-Refractory Patients with Progressive Multiple Myeloma after 1-3 Prior Lines of Therapy: Updated Results from CARTITUDE-2

Age, Sex and Self-Reported Race Differences in Immune Profiles of Hematologic Malignancy Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only